"Well differentiated thymic carcinoid tumours will be intensely avid on Dotatate PET, indicating the presence of somatostatin receptors14. Poorly differentiated neuroendocrine tumours may have variable/minimal intensity of Dotatate tracer uptake (these tumours are more likely to be FDG avid)."
"In-111–diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide "
"In-111–diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide"
"Most patients present with symptoms of mass effect or invasion of mediastinal and other thoracic structures, e.g. chest pain, cough, dyspnoea, and superior vena cava syndrome 7,15. Carcinoid syndrome is rare ("
"Carcinoid/NET of the thymus can be subtyped into 15:"
"Ga-68 Dotatate"
"In-111–diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide"
Expected headings
"Associations"
"Ga-68 Dotatate"
"F-18 FDG-PET"
"In-111–diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide "
"Affected patients are typically in the fourth or fifth decades of life. There is a recognised male predominance with M:F ratios around 3:1 2,7."
"Approximately 50% of thymic carcinoids are functionally active 6,7. Approximately 40% of patients have Cushing syndrome as a result of adrenocorticotropic hormone secretion by the tumour; these patients tend to have smaller lesions at the time of diagnosis since they present early with signs of corticosteroid excess. Up to 30% of patients have advanced-stage disease at presentation 6."
"History and etymology"